What does CUSIP 59102M104 represent in this 13F holders report?

CUSIP 59102M104 is the security identifier for MGX - Metagenomi Therapeutics, Inc. - COM used to aggregate holder disclosures.

How many institutions held MGX - Metagenomi Therapeutics, Inc. - COM in Q2 2024?

54 institutional investors reported MGX - Metagenomi Therapeutics, Inc. - COM for Q2 2024. Use the holders table for investor-level position and value details.

Metagenomi Therapeutics, Inc. - COM (MGX)

CUSIP: 59102M104

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class: Equity / COM
Total 13F shares: 12,188,453
Share change: -1,155,964
Total reported value: $49,568,061
Price per share: $4.08
Number of holders: 54
Value change: -$9,507,864
Number of buys: 28
Number of sells: 24

Quarterly Holders Quick Answers

What is CUSIP 59102M104?
CUSIP 59102M104 identifies MGX - Metagenomi Therapeutics, Inc. - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2024
Previous quarter: Q1 2024

Recent filing periods for CUSIP 59102M104:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of MGX - Metagenomi Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
RA CAPITAL MANAGEMENT, L.P.	13F	Company	— class O/S missing	1,744,415	$18,403,578	—	31 Mar 2024	13F
Novo Holdings A/S	13F 3/4/5	Company · 10%+ Owner	— class O/S missing	1,739,175	$18,348,296	—	31 Mar 2024	13F 3/4/5
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	— class O/S missing	1,343,201	$14,170,771	—	31 Mar 2024	13F
PFM Health Sciences, LP	13F	Company	— class O/S missing	1,267,002	$13,366,871	—	31 Mar 2024	13F
BAYER HEALTHCARE LLC	3/4/5	10%+ Owner	— class O/S missing	4,050,997	$11,666,871	—	13 Feb 2024	3/4/5
HHLR ADVISORS, LTD.	13F	Company	— class O/S missing	777,768	$8,205,452	—	31 Mar 2024	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	— class O/S missing	747,548	$7,573,455	—	31 Mar 2024	13F
CITADEL ADVISORS LLC	13F	Company	— class O/S missing	723,901	$7,518,546	—	31 Mar 2024	13F
Sebastian Bernales	3/4/5	Director	— mixed-class rows	3,147,422 mixed-class rows	$6,620,950	—	01 Apr 2024	3/4/5
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	— class O/S missing	583,041	$6,151,082	—	31 Mar 2024	13F
Sozo Ventures GP II, L.P.	13F	Company	— class O/S missing	581,577	$6,135,637	—	31 Mar 2024	13F
Deep Track Capital, LP	13F	Company	— class O/S missing	466,232	$4,918,748	—	31 Mar 2024	13F
PURA VIDA INVESTMENTS, LLC	13F	Company	— class O/S missing	461,283	$4,866,536	—	31 Mar 2024	13F
Point72 Asset Management, L.P.	13F	Company	— class O/S missing	371,100	$3,915,105	—	31 Mar 2024	13F
PRINCIPAL FINANCIAL GROUP INC	13F	Company	— class O/S missing	350,859	$3,701,563	—	31 Mar 2024	13F
Artal Group S.A.	13F	Company	— class O/S missing	300,000	$3,165,000	—	31 Mar 2024	13F
Frazier Life Sciences Management, L.P.	13F	Company	— class O/S missing	279,025	$2,943,714	—	31 Mar 2024	13F
ExodusPoint Capital Management, LP	13F	Company	— class O/S missing	227,556	$2,401,000	—	31 Mar 2024	13F
MARSHALL WACE, LLP	13F	Company	— class O/S missing	183,027	$1,930,934	—	31 Mar 2024	13F
VANGUARD GROUP INC	13F	Company	— class O/S missing	179,547	$1,894,221	—	31 Mar 2024	13F
Altitude Crest Partners Inc.	13F	Company	— class O/S missing	133,333	$1,406,663	—	31 Mar 2024	13F
Ghisallo Capital Management LLC	13F	Company	— class O/S missing	125,000	$1,318,750	—	31 Mar 2024	13F
BlackRock Finance, Inc.	13F	Company	— class O/S missing	114,324	$1,206,118	—	31 Mar 2024	13F
NORGES BANK	13F	Company	— class O/S missing	107,892	$1,138,261	—	31 Mar 2024	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	— class O/S missing	86,763	$915,349	—	31 Mar 2024	13F
Hudson Bay Capital Management LP	13F	Company	— class O/S missing	66,666	$703,326	—	31 Mar 2024	13F
LMR Partners LLP	13F	Company	— class O/S missing	52,058	$549,212	—	31 Mar 2024	13F
Simon Harnest	3/4/5	Title: Chief Investment Officer and Senior Vice President of Strategy	— mixed-class rows	171,239 mixed-class rows	$353,272	—	01 Apr 2024	3/4/5
HRT FINANCIAL LP	13F	Company	— class O/S missing	31,477	$332,000	—	31 Mar 2024	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	— class O/S missing	30,148	$318,061	—	31 Mar 2024	13F
Squarepoint Ops LLC	13F	Company	— class O/S missing	26,488	$279,448	—	31 Mar 2024	13F
Simren Delaney	3/4/5	Title: Vice President of Intellectual Property and Legal Operations	— mixed-class rows	123,037 mixed-class rows	$270,409	—	01 Apr 2024	3/4/5
Bramshill Investments, LLC	13F	Company	— class O/S missing	25,500	$269,025	—	31 Mar 2024	13F
WELLS FARGO & COMPANY/MN	13F	Company	— class O/S missing	24,894	$262,632	—	31 Mar 2024	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	— class O/S missing	22,009	$232,195	—	31 Mar 2024	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	— class O/S missing	20,159	$212,677	—	31 Mar 2024	13F
Laurion Capital Management LP	13F	Company	— class O/S missing	20,000	$211,000	—	31 Mar 2024	13F
Luis Borges	3/4/5	Chief Scientific Officer	— mixed-class rows	360,766 mixed-class rows	$199,630	—	01 Apr 2024	3/4/5
CITIGROUP INC	13F	Company	— class O/S missing	16,668	$175,847	—	31 Mar 2024	13F
Qube Research & Technologies Ltd	13F	Company	— class O/S missing	16,667	$175,837	—	31 Mar 2024	13F
JPMORGAN CHASE & CO	13F	Company	— class O/S missing	13,747	$145,031	—	31 Mar 2024	13F
NORTHERN TRUST CORP	13F	Company	— class O/S missing	13,053	$137,709	—	31 Mar 2024	13F
JANE STREET GROUP, LLC	13F	Company	— class O/S missing	12,330	$130,081	—	31 Mar 2024	13F
TEACHER RETIREMENT SYSTEM OF TEXAS	13F	Company	— class O/S missing	10,000	$106,000	—	31 Mar 2024	13F
Legal & General Group Plc	13F	Company	— class O/S missing	10,000	$105,800	—	31 Mar 2024	13F
Resolute Advisors LLC	13F	Company	— class O/S missing	10,000	$105,500	—	31 Mar 2024	13F
MORGAN STANLEY	13F	Company	— class O/S missing	9,205	$97,112	—	31 Mar 2024	13F
US BANCORP \DE\	13F	Company	— class O/S missing	4,500	$47,475	—	31 Mar 2024	13F
BANK OF AMERICA CORP /DE/	13F	Company	— class O/S missing	3,149	$33,222	—	31 Mar 2024	13F
UBS Group AG	13F	Company	— class O/S missing	1,680	$17,724	—	31 Mar 2024	13F

Institutional Holders of Metagenomi Therapeutics, Inc. - COM (MGX) as of Q2 2024

As of 30 Jun 2024, Metagenomi Therapeutics, Inc. - COM (MGX) was held by 54 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 12,188,453 shares. The largest 10 holders included Novo Holdings A/S, RA CAPITAL MANAGEMENT, L.P., FARALLON CAPITAL MANAGEMENT LLC, PFM Health Sciences, LP, HHLR ADVISORS, LTD., CITADEL ADVISORS LLC, EVENTIDE ASSET MANAGEMENT, LLC, Sozo Ventures GP II, L.P., Deep Track Capital, LP, and BlackRock Inc.. This page lists 54 institutional shareholders reporting positions in this security for the Q2 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders

Q2 2024 holders

Holder diff

Investor	Q1 2024 Shares	Q2 2024 Shares	Share Diff	Share Chg %	Q1 2024 Value $	Q2 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.